Polymeric microparticle systems for modified release of glucagon-like-peptide-1 receptor agonists

References

• An, T., et al., 2016. Sustained release of risperidone from biodegradable microspheres prepared by in-situ suspension-evaporation process. International journal of pharmaceutics, 503 (1–2), 8–15.
   PubMed Web of Science ®Google Scholar
• Aroda, V.R., 2018. A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials. Diabetes, obesity & metabolism, 20 (Suppl 1), 22–33.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 2021. Standards of medical care in diabetes 2021. Diabetes care, 44 (Supplement 1). https://care.diabetesjournals.org/content/44/Supplement_1
   Google Scholar
• Bailey, C.J., 2015. The current drug treatment landscape for diabetes and perspectives for the future. Clinical pharmacology and therapeutics, 98 (2), 170–184.
   PubMed Web of Science ®Google Scholar
• Balagani, P., et al., 2011. Microparticulate drug delivery system: a review. Indian journal of pharmaceutical science & research, 1, 19.
   Google Scholar
• Blevins, T., et al., 2011. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. Journal of clinical endocrinology and metabolism., 96 (5), 1301–1310.
   PubMed Web of Science ®Google Scholar
• Bolli, G.B., et al., 2014. Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabetic medicine, 31 (2), 176–184.
   PubMed Web of Science ®Google Scholar
• Buse, J.B., et al., 2010. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes care, 33 (6), 1255–1261.
   PubMed Web of Science ®Google Scholar
• Buse, J.B., et al., 2013. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. The lancet, 381 (9861), 117–124.
   PubMed Web of Science ®Google Scholar
• Buse, J.B., et al., 2009. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). The lancet, 374 (9683), 39–47.
   PubMed Web of Science ®Google Scholar
• Bush, M.A., et al., 2009. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes, obesity & metabolism, 11 (5), 498–505.
   PubMed Web of Science ®Google Scholar
• BYDUREON® Pen, a treatment option for adults with type 2 diabetes, now available in pharmacies. 2018. Available from: https://www.astrazeneca-us.com/media/press-releases/2014/bydureon-pen-now-available-in-pharmacies-20140908.html (Accessed 20 May 2018).
   Google Scholar
• Cho, N.H., et al., 2018. IDF diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes research and clinical practice, 138, 271–281.
   PubMed Web of Science ®Google Scholar
• Comolli, N. K., and Clark, C. E., 2013. Polymeric microparticles. In: Engineering polymer systems for improved drug delivery. Hoboken, NJ: John Wiley & Sons, Ltd, 85–116.
   Google Scholar
• Davies, M.J., et al., 2018. Management of hyperglycemia in type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care, 41 (12), 2669–2701.
   PubMed Web of Science ®Google Scholar
• Deacon, C.F., 2019. Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Frontiers in endocrinology, 10, 80.
   PubMed Web of Science ®Google Scholar
• Dharmalingam, M., Sriram, U., and Baruah, M.P., 2011. Liraglutide: a review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus. Indian journal of endocrinology and metabolism, 15 (1), 9–17.
   PubMedGoogle Scholar
• Diamant, M., et al., 2014. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. The lancet, diabetes & endocrinology, 2 (6), 464–473.
   PubMed Web of Science ®Google Scholar
• Drucker, D.J., and Nauck, M.A., 2006. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 368 (9548), 1696–1705.
   PubMed Web of Science ®Google Scholar
• Dungan, K.M., et al., 2014. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. The lancet, 384 (9951), 1349–1357.
   PubMed Web of Science ®Google Scholar
• Dungan, K.M., et al., 2016. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). Diabetes, obesity and metabolism, 18 (5), 475–482.
   PubMed Web of Science ®Google Scholar
• Eng, J., et al., 1992. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. The journal of biological chemistry, 267 (11), 7402–7405.
   PubMed Web of Science ®Google Scholar
• Fala, L., 2015. Trulicity (Dulaglutide): a new GLP-1 receptor agonist once-weekly subcutaneous injection approved for the treatment of patients with type 2 diabetes. American health & drug benefits, 8 (Spec Feature), 131–134.
   PubMedGoogle Scholar
• Fonseca, V.A., et al., 2012. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes care, 35 (6), 1225–1231.
   PubMed Web of Science ®Google Scholar
• Freitas, S., Merkle, H.P., and Gander, B., 2005. Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology. Journal of controlled release: official journal of the controlled release society, 102 (2), 313–332.
   PubMed Web of Science ®Google Scholar
• Gao, Z., et al., 2009. A novel DPP-IV-resistant analog of glucagon-like peptide-1 (GLP-1): KGLP-1 alone or in combination with long-acting PLGA microspheres. Peptides, 30 (10), 1874–1881.
   PubMed Web of Science ®Google Scholar
• Garber, A., et al., 2009. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. The lancet, 373 (9662), 473–481.
   PubMed Web of Science ®Google Scholar
• Garlotta, D., 2001. A literature review of Poly(Lactic Acid). Journal of polymers and the environment, 9 (2), 63–84.
   Web of Science ®Google Scholar
• Gu, B., and Burgess, D.J., 2015. Prediction of dexamethasone release from PLGA microspheres prepared with polymer blends using a design of experiment approach. International journal of pharmaceutics, 495 (1), 393–403.
   PubMed Web of Science ®Google Scholar
• Gupta, A.K., and Dey, B.K., 2013. Microencapsulation for controlled drug delivery: a comprehensive review. Sunsari technical college journal, 1 (1), 48–54.
   Google Scholar
• Gupta, V., 2013. Glucagon-like peptide-1 analogues: an overview. Indian journal of endocrinology and metabolism, 17 (3), 413–421.
   PubMedGoogle Scholar
• Hamad, K., et al., 2015. Properties and medical applications of polylactic acid: a review. Express polymer letters, 9 (5), 435–455.
   Web of Science ®Google Scholar
• Holst, J.J., et al., 1987. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS letters, 211 (2), 169–174.
   PubMed Web of Science ®Google Scholar
• Husain, M., et al., 2019. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England journal of medicine, 381 (9), 841–851.
   PubMed Web of Science ®Google Scholar
• Icart, L.P., de Souza Jr F G., and Lima, L.M.T.R., 2019. Sustained release and pharmacologic evaluation of human glucagon-like peptide-1 and liraglutide from polymeric microparticles. Journal of microencapsulation, 36 (8), 747–758.
   PubMed Web of Science ®Google Scholar
• Imeryüz, N., et al., 1997. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. The American journal of physiology, 273 (4), G920–927.
   PubMed Web of Science ®Google Scholar
• Iqbal, M., et al., 2015. Double emulsion solvent evaporation techniques used for drug encapsulation. International journal of pharmaceutics, 496 (2), 173–190.
   PubMed Web of Science ®Google Scholar
• Kadam, N.R., and Suvarna, V., 2015. Microsphere: a brief review. Asian journal of biomedical and pharmaceutical sciences, 5 (47), 13–19.
   Google Scholar
• Kaku, K., et al., 2018. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized trial. Diabetes, obesity and metabolism, 20 (5), 1202–1212.
   PubMed Web of Science ®Google Scholar
• Kolterman, O.G., et al., 2005. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. American journal of health-system pharmacy: AJHP: official journal of the American society of Health-System pharmacists, 62 (2), 173–181.
   PubMed Web of Science ®Google Scholar
• Kwak, H.-H., et al., 2009. Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats. Pharmaceutical research, 26 (11), 2504–2512.
   PubMed Web of Science ®Google Scholar
• Kwak, H.-H., et al., 2010. Efficacy of a new sustained-release microsphere formulation of exenatide, DA-3091, in Zucker diabetic fatty (ZDF) rats. European journal of pharmaceutical sciences: official journal of the European federation for pharmaceutical sciences, 40 (2), 103–109.
   PubMed Web of Science ®Google Scholar
• Lau, J., et al., 2015. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of medicinal chemistry, 58 (18), 7370–7380.
   PubMed Web of Science ®Google Scholar
• Lee, Y.-S., and Jun, H.-S., 2014. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism: clinical and experimental, 63 (1), 9–19.
   PubMed Web of Science ®Google Scholar
• Li, L., et al., 2005. Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia, 48 (7), 1339–1349.
   PubMed Web of Science ®Google Scholar
• Lim, S.M., et al., 2015. Evaluation of PEGylated exendin-4 released from poly (Lactic-co-Glycolic Acid) microspheres for antidiabetic therapy. Journal of pharmaceutical sciences, 104 (1), 72–80.
   PubMed Web of Science ®Google Scholar
• Lima, L.M.T.R., 2017. Prediabetes definitions and clinical outcomes. The lancet, diabetes & endocrinology, 5 (2), 92–93.
   PubMed Web of Science ®Google Scholar
• Lima, L.M.T.R., and Lima, L.M.T.R., 2017. Subclinical Diabetes. Anais da Academia Brasileira de Ciencias, 89 (1 Suppl 0), 591–614.
   PubMed Web of Science ®Google Scholar
• Makadia, H.K., and Siegel, S.J., 2011. Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers, 3 (3), 1377–1397.
   PubMed Web of Science ®Google Scholar
• Mao, S., et al., 2012. Recent advances in polymeric microspheres for parenteral drug delivery-part 1. Expert opinion on drug delivery, 9 (9), 1161–1176.
   PubMed Web of Science ®Google Scholar
• Marre, M., et al., 2009. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabetic medicine, 26 (3), 268–278.
   PubMed Web of Science ®Google Scholar
• Matthews, J.E., et al., 2008. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. The journal of clinical endocrinology and metabolism, 93 (12), 4810–4817.
   PubMed Web of Science ®Google Scholar
• Meinel, L., et al., 2001. Stabilizing insulin-like growth factor-I in poly(D,L-lactide-co-glycolide) microspheres. Journal of controlled release, 70 (1-2), 193–202.
   PubMed Web of Science ®Google Scholar
• Mentlein, R., Gallwitz, B., and Schmidt, W.E., 1993. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. European journal of biochemistry, 214 (3), 829–835.
   PubMedGoogle Scholar
• Midha, K., Nagpal, M., and Arora, S., 2015. Microspheres: a recent update. International journal of recent scientific research, 6 (8), 5859–5867.
   Google Scholar
• Nauck, M., et al., 2009. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes care, 32 (1), 84–90.
   PubMed Web of Science ®Google Scholar
• Nauck, M.A., et al., 2016. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia, 59 (2), 266–274.
   PubMed Web of Science ®Google Scholar
• Orskov, C., et al., 1994. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes, 43 (4), 535–539.
   PubMed Web of Science ®Google Scholar
• Park, J.-H., Earm, Y.E., and Song, D.-K., 2011. Cellular glucose availability and glucagon-like peptide-1. Progress in biophysics and molecular biology, 107 (2), 286–292.
   PubMed Web of Science ®Google Scholar
• Pérez-Rodriguez, C., et al., 2003. Stabilization of alpha-chymotrypsin at the CH2Cl2/water interface and upon water-in-oil-in-water encapsulation in PLGA microspheres. Journal of controlled release society, 89, 71–85.
   PubMed Web of Science ®Google Scholar
• Perignon, C., et al., 2015. Microencapsulation by interfacial polymerisation: membrane formation and structure. Journal of microencapsulation, 32 (1), 1–15.
   PubMed Web of Science ®Google Scholar
• Prasad-Reddy, L., and Isaacs, D., 2015. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs in context, 4, 212283.
   PubMedGoogle Scholar
• Pratley, R.E., et al., 2018. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet diabetes and endocrinology., 6 (4), 275–286.
   PubMed Web of Science ®Google Scholar
• Pratley, R.E., et al., 2014. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. The lancet, diabetes & endocrinology, 2 (4), 289–297.
   PubMed Web of Science ®Google Scholar
• Patel, R., et al., 2011. Microsphere as a novel drug delivery. International journal of pharmacy and life sciences, 2, 992–997.
   Google Scholar
• “Really Good” New Guidelines for T2 Diabetes [WWW Document]. 2018. Medscape. URL http://www.medscape.com/viewarticle/899120 (Accessed 9 September 2018).
   Google Scholar
• Reddy, K.R., 2000. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Annals of pharmacotherapy, 34 (7–8), 915–923.
   PubMed Web of Science ®Google Scholar
• Rena, G., Hardie, D.G., and Pearson, E.R., 2017. The mechanisms of action of metformin. Diabetologia, 60 (9), 1577–1585.
   PubMed Web of Science ®Google Scholar
• Reusch, J., et al., 2014. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. Diabetes, obesity and metabolism, 16 (12), 1257–1264.
   PubMed Web of Science ®Google Scholar
• Rosenstock, J., 2014. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes care, 37 (8), 2317–2325.
   PubMed Web of Science ®Google Scholar
• Russell-Jones, D., et al., 2012. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes care, 35 (2), 252–258.
   PubMed Web of Science ®Google Scholar
• Russell-Jones, D., et al., 2009. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia, 52 (10), 2046–2055.
   PubMed Web of Science ®Google Scholar
• Sahil, K., et al., 2011. Microsphere: a review. International journal of research in pharmacy and chemistry, 1, 2231–2781.
   Google Scholar
• Schwartz, S.S., et al., 2016. The time is right for a new classification system for diabetes: rationale and implications of the β-cell-centric classification schema. Diabetes care, 39 (2), 179–186.
   PubMed Web of Science ®Google Scholar
• Seino, Y., et al., 2018. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes, obesity and metabolism, 20 (2), 378–388.
   PubMed Web of Science ®Google Scholar
• Sekar, R., et al., 2016., Chapter seven – pharmacological actions of glucagon-like peptide-1, gastric inhibitory polypeptide, and glucagon. In: Jeon, K.W., Galluzzi, L, eds. International review of cell and molecular biology, international review of cell and molecular biology. Cambridge: Academic Press, 279–341. https://doi.org/10.1016/bs.ircmb.2016.05.002
   Google Scholar
• Singh, M.N., et al., 2010. Microencapsulation: a promising technique for controlled drug delivery. Research in pharmaceutical sciences, 5 (2), 65–77.
   PubMedGoogle Scholar
• Stassen, S., et al., 1994. Microencapsulation by coacervation of poly(lactide-co-glycolide): 1. physicochemical characteristics of the phase separation process. Polymer, 35 (4), 777–785.
   Web of Science ®Google Scholar
• Thomas, S., et al., 2013. Handbook of biopolymer-based materials: from blends and composites to gels and complex networks. Weinheim: Wiley.
   Google Scholar
• Thomasin, C., et al., 1996. A contribution to overcoming the problem of residual solvents in biodegradable microspheres prepared by coacervation. European journal of pharmaceutics and biopharmaceutics, 42, 16–24.
   Web of Science ®Google Scholar
• Tian, L., et al., 2010. Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology, 151 (7), 3049–3060.
   PubMed Web of Science ®Google Scholar
• Wang, J., Wang, B.M., and Schwendeman, S.P., 2002. Characterization of the initial burst release of a model peptide from poly(D,L-lactide-co-glycolide) microspheres. Journal of controlled release, 82 (2–3), 289–307.
   PubMed Web of Science ®Google Scholar
• Wang, Y., et al., 2016. Exenatide loaded PLGA microspheres for long-acting antidiabetic therapy: preparation, characterization, pharmacokinetics and pharmacodynamics. RSC advances, 6 (44), 37452–37462.
   Web of Science ®Google Scholar
• Weissman, P.N., et al., 2014. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia, 57 (12), 2475–2484.
   PubMed Web of Science ®Google Scholar
• Werner, U., et al., 2010. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regulatory peptides, 164 (2–3), 58–64.
   PubMedGoogle Scholar
• Wettergren, A., Wøjdemann, M., and Holst, J.J., 1998. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. American Journal of Physiology, 275 (5), G984–G992.
   PubMed Web of Science ®Google Scholar
• Wilkins, J.J., et al., 2014. A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes. Journal of clinical pharmacology, 54 (3), 267–278.
   PubMed Web of Science ®Google Scholar
• Wong, C.Y., Al-Salami, H., and Dass, C.R., 2018. Microparticles, microcapsules and microspheres: a review of recent developments and prospects for oral delivery of insulin. International journal of pharmaceutics, 537 (1–2), 223–244.
   PubMed Web of Science ®Google Scholar
• Wu, J., et al., 2016. Liraglutide-loaded poly(lactic-co-glycolic acid) microspheres: preparation and in vivo evaluation. European journal of pharmaceutical sciences: official journal of the European federation for pharmaceutical sciences, 92, 28–38.
   PubMed Web of Science ®Google Scholar
• Wysham, C., et al., 2011. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabetic medicine: a journal of the British diabetic association, 28 (6), 705–714.
   PubMed Web of Science ®Google Scholar
• Xu, F., et al., 2017. Modified human glucagon-like peptide-1 (GLP-1) produced in E. coli has a long-acting therapeutic effect in type 2 diabetic mice. PLoS one, 12 (7), e0181939.
   PubMed Web of Science ®Google Scholar
• Xuan, J., et al., 2013. Exenatide-loaded PLGA microspheres with improved glycemic control: in vitro bioactivity and in vivo pharmacokinetic profiles after subcutaneous administration to SD rats. Peptides, 46, 172–179.
   PubMed Web of Science ®Google Scholar
• Yin, D., et al., 2008. Preparation of glucagon-like peptide-1 loaded PLGA microspheres: characterizations, release studies and bioactivities in vitro/in vivo. Chemical & pharmaceutical bulletin, 56 (2), 156–161.
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen, H., 2004. Thiazolidinediones. The New England journal of medicine, 351 (11), 1106–1118.
   PubMed Web of Science ®Google Scholar
• Zinman, B., et al., 2009. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD. Diabetes care, 32 (7), 1224–1230.
   PubMed Web of Science ®Google Scholar